Physician profile
Steven Lee Wise
NPI 1740262211
$136,703.23
in general payments reported to CMS, 2019-2025
39 companies · $9,820 in 2025
The $9,820 reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,610 · 2020: $17K · 2021: $26K · 2022: $10K · 2023: $62K · 2024: $5,918 · 2025: $9,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $12K · Travel and Lodging: $5,318 · Consulting Fee: $4,500 · Honoraria: $2,084 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,575.00 |
| Food and Beverage | $11,972.44 |
| Travel and Lodging | $5,318.28 |
| Consulting Fee | $4,500.00 |
| Honoraria | $2,084.00 |
| Education | $251.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $93,203.01 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $8,016.22 | 2020-2023 | Airduo Digihaler |
| Astrazeneca Pharmaceuticals LP | $7,357.42 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Genentech USA, INC. | $5,483.10 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $4,083.43 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $3,712.94 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $2,996.31 | 2021-2025 | Ayvakit |
| Genzyme Corporation | $2,092.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,890.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,854.72 | 2019-2025 | |
| Csl Behring | $680.77 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $677.25 | 2020-2025 | Eohilia, Cuvitru |
| Grifols USA, LLC | $586.33 | 2020-2025 | Xembify |
| Amgen INC. | $501.34 | 2022-2025 | Tezspire |
| Optinose US, INC. | $441.97 | 2019-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $400.30 | 2023-2025 | Xolair |
| Kaleo, INC. | $367.51 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $301.40 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $235.26 | 2020-2025 | |
| Octapharma USA, INC. | $231.43 | 2019-2025 | Cutaquig |
| Abbott Laboratories | $208.32 | 2020-2022 | |
| Pharming Healthcare, INC. | $170.31 | 2024-2025 | Ruconest |
| Galderma Laboratories, L.P. | $167.15 | 2025 | Nemluvio |
| Covis Pharma Gmbh | $164.55 | 2019-2022 | |
| Shire North American Group INC | $133.27 | 2019 | |
| Abbvie INC. | $118.36 | 2022 | |
| Mylan Specialty L.P. | $112.55 | 2019 | |
| Ionis Pharmaceuticals, INC. | $90.36 | 2025 | Dawnzera, Donidalorsen |
| Hospira, INC. | $77.73 | 2019-2025 | |
| Bio Products Laboratory USA, INC. | $64.83 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $58.54 | 2021-2023 | Orladeyo |
| Merck Sharp & Dohme LLC | $47.95 | 2021-2023 | |
| Incyte Corporation | $38.99 | 2025 | Opzelura |
| Leo Pharma INC. | $35.89 | 2022 | |
| Hikma Pharmaceuticals USA | $33.20 | 2023-2024 | Ryaltris |
| Sunovion Pharmaceuticals INC. | $23.88 | 2019 | |
| Adma Biomanufacturing LLC | $18.96 | 2022 | |
| Alk-Abello, INC | $12.59 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.